Substituted oxadiazoles: a patent review (2010 – 2012)

Bibliography

• Clapp LB. Comprehensive heterocyclic chemistry. Oxford: Pergamon Press, UK; 1984
   Google Scholar
• Johns B, Weatherhead JG, Allen SH, et al. 1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position. Bioorg Med Chem Lett 2009;19:1807-10
   PubMed Web of Science ®Google Scholar
• Llinàs-Brunet M, Bailey MD, Bolger G, et al. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. J Med Chem 2004;47:1605-8
   PubMed Web of Science ®Google Scholar
• Alia MA, Shaharyar M. Oxadiazole mannich bases: synthesis and antimycobacterial activity. Bioorg Med Chem Lett 2007;17:3314-16
   PubMedGoogle Scholar
• Lee L, Robb LM, Davis R, et al. Design, synthesis, and biological evaluations of 2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoline analogs of combretastatin-A4. J Med Chem 2010;53:325-34
   PubMed Web of Science ®Google Scholar
• Kiselyov AS, Semenova MN, Chernyshova NB, et al. Novel derivatives of 1,3,4-oxadiazoles are potent mitostatic agents featuring strong microtubule depolymerizing activity in the sea urchin embryo and cell culture assays. Eur J Med Chem 2010;45:1683-97
   PubMed Web of Science ®Google Scholar
• Bankar GR, Nandakumar K, Nayak PG, et al. Vasorelaxant effect in rat aortic rings through calcium channel blockage: a preliminary in vitro assessment of a 1,3,4-oxadiazole derivative. Chem Biol Interact 2009;181:377-82
   PubMed Web of Science ®Google Scholar
• Schiefer IT, VandeVrede L, Fa' M, et al. Furoxans (1,2,5-Oxadiazole-N-Oxides) as novel NO mimetic neuroprotective and procognitive agents. J Med Chem 2012;55:3076-87
   PubMedGoogle Scholar
• Iqbal AKM, Khan AY, Kalashetti MB, et al. Synthesis, hypoglycemic and hypolipidemic activities of novel thiazolidinedione derivatives containing thiazole/triazole/oxadiazole ring. Eur J Med Chem 2012;53:308-15
   PubMed Web of Science ®Google Scholar
• Ghani U, Ullah N. New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triazole-5(4H)-thiones, and substituted hydrazides to the dicopper active site. Bioorg Med Chem 2010;18:4042-8
   PubMed Web of Science ®Google Scholar
• Zarghi A, Hajimahdi Z, Mohebbi S, et al. Design and synthesis of new 2-substituted-5-[2-(2-halobenzyloxy)phenyl]-1,3,4-oxadiazoles as anticonvulsant agents. Chem Pharm Bull 2008;56:509-12
   PubMed Web of Science ®Google Scholar
• Zarghi A, Tabatabai SA, Faizi M, et al. Synthesis and anticonvulsant activity of new 2-substituted-5-(2-benzyloxyphenyl)-1,3,4-oxadiazoles. Bioorg Med Chem Lett 2005;15:1863-5
   PubMed Web of Science ®Google Scholar
• Warrener RN. New adventures in the synthesis of hetero-bridged syn-facially fused norbornadienes ("[n]polynorbornadienes") and their topological diversity. Eur J Org Chem 2000;65:3363-80
   Google Scholar
• Boström J, Hogner A, Llinàs A, et al. Oxadiazoles in medicinal chemistry. J Med Chem 2012;55:1817-30
   PubMed Web of Science ®Google Scholar
• Amir M, Shikha K. Synthesis and anti-inflammatory, analgesic, ulcerogenic and lipid peroxidation activities of some new 2-[(2,6-dichloroanilino)phenyl]acetic acid derivatives. Eur J Med Chem 2004;39:535-45
   PubMed Web of Science ®Google Scholar
• Zheng X, Li Z, Wang Y, et al. Synthesis and Insecticidal activities of novel 2,5-disubstituted 1,3,4-oxadiazoles. J Fluorine Chem 2003;123:163-9
   Web of Science ®Google Scholar
• Cui L, Liu Q, Yu J, et al. A novel one-pot synthesis of a-keto-1,3,4-oxadiazole derivatives based on isocyanide-Nef reaction. Tetrahedron Lett 2011;52:5530-3
   Web of Science ®Google Scholar
• Adib M, Ansari S, Fatemi S, et al. A multi-component synthesis of 3-aryl-1-(arylmethylideneamino)pyrrolidine-2,5-diones. Tetrahedron 2010;66:2723-7
   Google Scholar
• Adib M, Ansari S, Feizi S, et al. An efficient three-component synthesis of 3-(1-Hydroxyalkyl)[1,2,4]-triazolo[4,3-c]quinazolines. Synlett 2010;6:921-3
   Google Scholar
• Ramazani A, Ahmadi Y, Rouhani M, et al. The reaction of (N-isocyanimino)triphenylphosphorane with an electron-poor α-haloketone in the presence of aromatic carboxylic acids: A novel three-component reaction for the synthesis of disubstituted 1,3,4-oxadiazole derivatives. Heteroat Chem 2010;21:368-72
   Web of Science ®Google Scholar
• Ramazani A, Rezaei A. Novel one-pot, four-component condensation reaction: an efficient approach for the synthesis of 2,5-disubstituted 1,3,4-oxadiazole derivatives by a Ugi-4CR/aza-wittig sequence. Org Lett 2010;12:2852-5
   PubMed Web of Science ®Google Scholar
• Ramazani A, Ahmadi Y, Mahyari A. One-pot efficient synthesis of fully substituted 1,3,4-oxadiazole derivatives from (N-isocyanimino)triphenylphosphorane, carboxylic acids, and aromatic bis-aldehydes. Synthetic Commun 2011;41:2273-82
   Web of Science ®Google Scholar
• Ramazani A, Nasrabadi FZ, Ahmadi Y. One-pot, four-component synthesis of fully substituted 1,3,4-oxadiazole derivatives from (Isocyanoimino)triphenylphosphorane, a primary amine, an aromatic carboxylic acid, and chloroacetone. Helv Chim Acta 2011;94:1024-9
   Web of Science ®Google Scholar
• Ramazani A, Kalhor R, Rezaei A, et al. Four-component synthesis of disubstituted 1,3,4-oxadiazole derivatives from cinnamaldehyde, an aromatic carboxylic acid, a secondary amine, and N-isocyaniminotriphenylphosphorane. Heteroat Chem 2012;23:315-21
   Web of Science ®Google Scholar
• El-Sayed WA, Ali OM, Hendy HA, et al. Synthesis and antimicrobial activity of new 2,5-disubstituted 1,3,4-oxadiazoles and 1,2,4-triazoles and their sugar derivatives. Chin J Chem 2012;30:77-83
   Web of Science ®Google Scholar
• Rajak H, Agarawal A, Parmar P, et al. 2,5-disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors. Bioorg Med Chem Lett 2011;21:5735-8
   PubMed Web of Science ®Google Scholar
• Dolman SJ, Gosselin F, O'shea PD, et al. Superior reactivity of thiosemicarbazide in the synthesis of 2-amino-1,3,4-oxadizaoles. J Org Chem 2006;71:9548-51
   PubMed Web of Science ®Google Scholar
• Patel NB, Patel JC. Synthesis and antimicrobial activity of 3-(1,3,4-oxadiazol-2-il)quinazolin-4(3H)-ones. Sci Pharm 2010;78:171-93
   PubMedGoogle Scholar
• Ontoria JM, Bufi LL, Torrisi C, et al. Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors. Bioorg Med Chem Lett 2011;21:5274-82
   PubMed Web of Science ®Google Scholar
• Singh H, Yadav MR, Garg SP, et al. Steroids and related studies. Part 73. Steroidal[3,2-c]-1',2',5'-oxadiazoles. Heterocycles 1985;23:2931-8
   Google Scholar
• Ruccia M, Vivona N, Spinelli D. Mononuclear heterocyclic rearrangements. Adv Heterocycl Chem 1981;29:141-69
   Google Scholar
• Chen HC, Farese RVJ. DGAT and triglyceride synthesis: a new target for obesity treatment? Trends Cardiovasc Med 2000;10:188-92
   PubMed Web of Science ®Google Scholar
• Farese RVJ, Cases S, Smith S. Triglyceride synthesis: insights from the cloning of diacylglycerol acyltransferase. J Curr Opin Lipidol 2000;11:229-34
   PubMed Web of Science ®Google Scholar
• McCoull W, Addie MS, Birch AM, et al. Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. Bioorg Med Chem Lett 2012;22:3873-8
   PubMed Web of Science ®Google Scholar
• Olias G, Viollet C, Kusserow H, et al. Regulation and function of somatostatin receptors. J Neurochem 2004;89:1057-91
   PubMed Web of Science ®Google Scholar
• Pasternak A, Feng Z, deJesus R, et al. Stimulation of glucose-dependent insulin secretion by a potent, selective sst3 antagonist. ACS Med Chem Lett 2012;3:289-93
   PubMedGoogle Scholar
• He S, Ye Z, Truong Q, et al. The discovery of MK-4256, a potent SSTR3 antagonist as a potential treatment of type 2 diabetes. ACS Med Chem Lett 2012;3:484-9
   PubMedGoogle Scholar
• Zhang Z, Lee SY. PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity. Exp Opin Investig Drugs 2003;12:223-33
   PubMed Web of Science ®Google Scholar
• Elchebly M, Payette P, Michaliszyn E, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999;283:1544-8
   PubMed Web of Science ®Google Scholar
• Gallic S, Hauser C, Kahn B, et al. Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP. Mol Cell Biol 2005;2:819-29
   Google Scholar
• Basu S, Prasad UV, Barawkar DA, et al. Discovery of novel and potent heterocyclic carboxylic acid derivatives as protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem Lett 2012;22:2843-9
   PubMedGoogle Scholar
• Ladenheim EE, Hamilton NL, Behles RR, et al. Factors contributing to obesity in bombesin receptor subtype-3-deficient mice. Endocrinology 2008;149:971-8
   PubMed Web of Science ®Google Scholar
• Chobanian HR, Guo Y, Liu P, et al. The design and synthesis of potent, selective benzodiazepine sulfonamide bombesin receptor subtype 3 (BRS-3) agonists with an increased barrier of atropisomerization. Bioorg Med Chem 2012;20:2845-9
   PubMed Web of Science ®Google Scholar
• Chobanian HR, Guo Y, Liu P, et al. Discovery of MK-7725, a potent, selective bombesin receptor subtype-3 agonist for the treatment of obesity. ACS Med Chem Lett 2012;3:252-6
   PubMed Web of Science ®Google Scholar
• Bhat MA, Al-Omar MA, Siddiqui N. Synthesis, anticonvulsant and neurotoxicity of some novel 1,3,4-oxadiazole derivatives of phthalimide. Der Pharm Chem 2010;2:1-10
   Google Scholar
• Kaur H, Kumar S, Lata S, et al. Synthesis of some new triazolyl/oxadiazolyl/thiadiazolylphenothiazines as anticonvulsant agents. Eur J Med Chem 2010; doi: 10.1016/j.ejmech.2010.07.047
   Google Scholar
• Rajak H, Deshmukh R, Veerasamy R, et al. Novel semicarbazones based 2,5-disubstituted-1,3,4-oxadiazoles: one more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity. Bioorg Med Chem Lett 2010;20:4168-72
   PubMed Web of Science ®Google Scholar
• Rajak H, Thakur BS, Singh A, et al. Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity. Bioorg Med Chem Lett 2013;23:864-8
   PubMed Web of Science ®Google Scholar
• Crawford JH, Wainwright A, Heavens R, et al. Mobilisation of intracellular Ca2+by mGluR5 metabotropic glutamate receptor activation in neonatal rat cultured dorsal root ganglia neurones. Neuropharmacology 2000;39:621-30
   PubMedGoogle Scholar
• Spooren WP, Vassout A, Neijt HC, et al. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 2000;295:1267-75
   PubMed Web of Science ®Google Scholar
• Chapman AG, Nanan K, Williams M, et al. Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893). Neuropharmacology 2000;39:1567-74
   PubMed Web of Science ®Google Scholar
• Movsesyan VA, O'Leary DM, Fan L, et al. mGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine and (E)-2-methyl- 6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 2001;296:41-7
   PubMed Web of Science ®Google Scholar
• Wágner G, Wéber C, Nyéki O, et al. Hit-to-lead optimization of disubstituted oxadiazoles and tetrazoles as mGluR5 NAMs. Bioorg Med Chem Lett 2010;20:3737-41
   PubMedGoogle Scholar
• Raboisson P, Breitholtz-Emanuelsson A, Dahllöf H, et al. Discovery and characterization of AZD9272 and AZD6538—two novel mGluR5 negative allosteric modulators selected for clinical development. Bioorg Med Chem Lett 2012;22:6974-9
   PubMedGoogle Scholar
• Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4
   PubMed Web of Science ®Google Scholar
• Turcotte D, Dorze JA, Esfahani F, et al. Examining the roles of cannabinoids in pain and other therapeutic indications: a review. Expert Opin Pharmacother 2010;11:17-31
   PubMed Web of Science ®Google Scholar
• Kiyoi T, Adam JM, Clark JK, et al. Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists. Bioorg Med Chem Lett 2011;21:1748-53
   PubMedGoogle Scholar
• Morrison AJ, Adam JM, Baker JA, et al. Design, synthesis, and structure–activity relationships of indole-3-heterocycles as agonists of the CB1 receptor. Bioorg Med Chem Lett 2011;21:506-9
   PubMedGoogle Scholar
• Adam JM, Clark JK, Davies K, et al. Low brain penetrant CB1 receptor agonists for the treatment of neuropathic pain. Bioorg Med Chem Lett 2012;22:2932-7
   PubMedGoogle Scholar
• Pagotto U, Marsicano G, Cota D, et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrinol Rev 2006;27:73-100
   PubMed Web of Science ®Google Scholar
• Hildebrandt AL, Kelly-Sullivan DM, Black SC. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 2003;462:125-32
   PubMed Web of Science ®Google Scholar
• Sasmal PK, Talwar R, Swetha J, et al. Structure–activity relationship studies of novel pyrazole and imidazole carboxamides as cannabinoid-1 (CB1) antagonists. Bioorg Med Chem Lett 2011;21:4913-18
   PubMedGoogle Scholar
• Temesgen Z, Siraj DS. Raltegravir: first in class HIV integrase inhibitor. Ther Clin Risk Manage 2008;4:493-500
   PubMedGoogle Scholar
• Wang Z, Wang M, Yao X, et al. Hydroxyl may not be indispensable for raltegravir: design, synthesis and SAR studies of raltegravir derivatives as HIV-1 inhibitors. Eur J Med Chem 2012;50:361-9
   PubMedGoogle Scholar
• Hajimahdi Z, Zarghi A, Zabihollahi R, et al. Synthesis, biological evaluation, and molecular modeling studies of new 1,3,4-oxadiazole- and 1,3,4-thiadiazole-substituted 4-oxo-4H-pyrido[1,2-a]pyrimidines as anti-HIV-1 agents. Med Chem Res 2012; doi: 10.1007/s00044-012-0241-5
   Google Scholar
• Leung CS, Zeevaart JG, Domaoal RA, et al. Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives. Bioorg Med Chem Lett 2010;20:2485-8
   PubMed Web of Science ®Google Scholar
• Kumar DV, Rai R, Brameld KA, et al. 3-Heterocyclyl quinolone inhibitors of the HCV NS5B polymerase. Bioorg Med Chem Lett 2012;22:300-4
   PubMedGoogle Scholar
• Mittapalli GK, Zhao F, Jackson A, et al. Discovery of ITX 4520: a highly potent orally bioavailable hepatitis C virus entry inhibitor. Bioorg Med Chem Lett 2012;22:4955-61
   PubMedGoogle Scholar
• Tung JS, Davis DL, Anderson JP, et al. Design of substrate-based inhibitors of human β-secretase. J Med Chem 2002;45:259-62
   PubMed Web of Science ®Google Scholar
• Shuto D, Kasai S, Kimura T, et al. KMI-008, a novel beta-secretase inhibitor containing a hydroxymethylcarbonyl isostere as a transition-state mimic: design and synthesis of substrate-based octapeptides. Bioorg Med Chem Lett 2003;13:4273-6
   PubMed Web of Science ®Google Scholar
• Kimura T, Shuto D, Hamada Y, et al. Design and synthesis of highly active Alzheimer's beta-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability. Bioorg Med Chem Lett 2005;15:211-15
   PubMed Web of Science ®Google Scholar
• Tagad HD, Hamada Y, Nguyen J-T, et al. Design of pentapeptidic BACE1 inhibitors with carboxylic acid bioisosteres at P'1 and P4 positions. Bioorg Med Chem 2010;18:3175-86
   PubMed Web of Science ®Google Scholar
• Rajapakse HA, Nantermet PG, Selnick HG, et al. SAR of tertiary carbinamine derived BACE1 inhibitors: role of aspartate ligand amine pKa in enzyme inhibition. Bioorg Med Chem Lett 2010;20:1885-9
   PubMed Web of Science ®Google Scholar
• Zhu H, Young MB, Nantermet PG, et al. Rapid P1 SAR of brain penetrant tertiary carbinamine derived BACE inhibitors. Bioorg Med Chem Lett 2010;20:1779-82
   PubMed Web of Science ®Google Scholar
• Bondock S, Adel S, Etman HA, et al. Synthesis and antitumor evaluation of some new 1,3,4-oxadiazole-based heterocycles. Eur J Med Chem 2012;48:192-9
   PubMed Web of Science ®Google Scholar
• Kamal A, Dastagiri D, Ramaiah MJ, et al. Synthesis, anticancer activity and mitochondrial mediated apoptosis inducing ability of 2,5-diaryloxadiazole–pyrrolobenzodiazepine conjugates. Bioorg Med Chem 2010;18:6666-77
   PubMedGoogle Scholar
• Hu Y, Lu X, Chen K, et al. Design, synthesis, biological evaluation and molecular modeling of 1,3,4-oxadiazoline analogs of combretastatin-A4 as novel antitubulin agents. Bioorg Med Chem 2012;20:903-9
   PubMed Web of Science ®Google Scholar
• Hiscox S, Barnfather P, Hayes E, et al. Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells. Breast Cancer Res Treat 2011;125:659-69
   PubMedGoogle Scholar
• Gabarra-Niecko V, Schaller MD, Dunty JM. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev 2003;22:359-74
   PubMed Web of Science ®Google Scholar
• Zhang L-R, Liu Z-J, Zhang H, et al. Synthesis, biological evaluation and molecular docking studies of novel 2-(1,3,4-oxadiazol-2-ylthio)-1-phenylethanone derivatives. Bioorg Med Chem 2012;20:3615-21
   PubMedGoogle Scholar
• Blangy A, Lane HA, d'Hérin P, et al. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 1995;83:1159-69
   PubMed Web of Science ®Google Scholar
• Array BioPhrma, Inc. Mitotic Kinesin inhibitors and methods of use thereof patent. US8236825; 2012
   Google Scholar
• Logan GJ, Smyth CMF, Earl JW, et al. HeLa cells cocultured with peripheral blood lymphocytes acquire an immuno-inhibitory phenotype through up-regulation of indoleamine 2,3-dioxygenase activity. Immunology 2002;105:478-87
   PubMedGoogle Scholar
• Wichers MC, Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-α-induced depression. J Psychiatry Neurosci 2004;29:11-17
   PubMed Web of Science ®Google Scholar
• Incyte Corp. 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase patent. US20120058079; 2012
   Google Scholar
• PTC Therapeutics, Inc. 1,2,4-Oxadiazole benzoic acid compositions and their use in bioassays patent. US8017636; 2011
   Google Scholar
• PTC Therapeutics, Inc. Pharmaceutical composition of 1,2,4-oxadiazole benzoic acid and their use for the treatment of disease patent. US8227494; 2012
   Google Scholar
• PTC Therapeutics, Inc. Methods for the synthesis of 1,2,4-oxadiazole benzoic acid compounds patent. US8129540; 2012
   Google Scholar
• PTC Therapeutics, Inc. 1,2,4-Oxadiazole benzoic acid compositions patent. US8163782; 2012
   Google Scholar
• Torphy TJ, Undem BJ. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 1991;46:512-23
   PubMed Web of Science ®Google Scholar
• Mitchell CJ, Ballantine SP, Coe DM, et al. Pyrazolopyridines as potent PDE4B inhibitors: 5-Heterocycle SAR. Bioorg Med Chem Lett 2010;20:5803-6
   PubMed Web of Science ®Google Scholar
• Dekhane DV, Pawar SS, Gupta S, et al. Synthesis and anti-inflammatory activity of some new 4,5-dihydro-1,5-diaryl-1H-pyrazole-3-substituted-heteroazole derivatives. Bioorg Med Chem Lett 2011;21:6527-32
   PubMed Web of Science ®Google Scholar
• Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Disc 2003;2:717-26
   PubMed Web of Science ®Google Scholar
• Tynebor RM, Chen MH, Natarajan SR, et al. Synthesis and biological activity of 2H-quinolizin-2-one based p38α MAP kinase inhibitors. Bioorg Med Chem Lett 2010;20:2765-9
   PubMedGoogle Scholar
• Gilani SJ, Khan SA, Siddiqui N. Synthesis and pharmacological evaluation of condensed heterocyclic 6-substituted 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole and 1,3,4-oxadiazole derivatives of isoniazid. Bioorg Med Chem Lett 2010;20:4762-5
   PubMed Web of Science ®Google Scholar
• Zhang Z-M, Zhang X-W, Zhao Z-Z, et al. Synthesis, biological evaluation and molecular docking studies of 1,3,4-oxadiazole derivatives as potential immunosuppressive agents. Bioorg Med Chem 2012;20:3359-67
   PubMedGoogle Scholar
• Tang J-F, Lv X-H, Wang X-A, et al. Design, synthesis, biological evaluation and molecular modeling of novel 1,3,4-oxadiazole derivatives based on vanillic acid as potential immunosuppressive agents. Bioorg Med Chem 2012;20:4226-36
   PubMed Web of Science ®Google Scholar
• Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 2005;23:127-59
   PubMed Web of Science ®Google Scholar
• Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol 2009;158:1173-82
   PubMed Web of Science ®Google Scholar
• Buzard D, Han S, Thoresen L, et al. Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P1 agonists. Bioorg Med Chem Lett 2011;21:6013-18
   PubMedGoogle Scholar
• Meng Q, Zhao B, Xu Q, et al. Indole-propionic acid derivatives as potent, S1P3-sparing and EAE efficacious sphingosine-1-phosphate 1 (S1P1) receptor agonists. Bioorg Med Chem Lett 2012;22:2794-7
   PubMedGoogle Scholar
• Buzard DJ, Han S, Lopez L, et al. Fused tricyclic indoles as S1P1 agonists with robust efficacy in animal models of autoimmune disease. Bioorg Med Chem Lett 2012;22:4404-9
   PubMedGoogle Scholar
• Hale JJ, Lynch CL, Neway W, et al. A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists. J Med Chem 2004;47:6662-5
   PubMed Web of Science ®Google Scholar
• Nakamura T, Asano M, Sekiguchi Y, et al. Discovery of CS-2100, a potent, orally active and S1P3-sparing S1P1 agonist. Bioorg Med Chem Lett 2012;22:1788-92
   PubMedGoogle Scholar
• Merck Serono SA. Pyrazole oxadiazole derivatives as S1P1 agonists patent. US20120071460; 2012
   Google Scholar
• Glaxo Group Ltd. Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists patent. US8324254; 2012
   Google Scholar
• Chandrakantha B, Shetty P, Nambiyar V, et al. Synthesis, characterization and biological activity of some new 1,3,4-oxadiazole bearing 2-flouro-4-methoxy phenyl moiety. Eur J Med Chem 2010;45:1206-10
   PubMed Web of Science ®Google Scholar
• Bakht MA, Shahar Yar M, Abdel-Hamid SG, et al. Molecular properties prediction, synthesis and antimicrobial activity of some newer oxadiazole derivatives. Eur J Med Chem 2010;45:5862-9
   PubMed Web of Science ®Google Scholar
• Shelke S, Mhaske G, Gadakh S, et al. Green synthesis and biological evaluation of some novel azoles as antimicrobial agents. Bioorg Med Chem Lett 2010;20:7200-4
   PubMed Web of Science ®Google Scholar
• Kumar R, Kumar A, Jain S, et al. Synthesis, antibacterial evaluation and QSAR studies of 7-[4-(5-aryl-1,3,4-oxadiazole-2-yl)piperazinyl] quinolone derivatives. Eur J Med Chem 2011;46:3543-50
   PubMed Web of Science ®Google Scholar
• Sridhara AM, Reddy KRV, Keshavayya J, et al. Synthesis and antimicrobial activity of 2-substituted [4-(1,3,4-oxadiazol-2-yl methyl)] phthalazin-1(2H)-one derivatives. Eur J Med Chem 2010;45:4983-9
   PubMedGoogle Scholar
• Rane RA, Gutte SD, Sahu NU. Synthesis and evaluation of novel 1,3,4-oxadiazole derivatives of marine bromopyrrole alkaloids as antimicrobial agent. Bioorg Med Chem Lett 2012;22:6429-32
   PubMedGoogle Scholar
• Ishii M, Jorge SD, de Oliveira AA, et al. Synthesis, molecular modeling and preliminary biological evaluation of a set of 3-acetyl-2,5-disubstituted-2,3-dihydro-1,3,4-oxadiazole as potential antibacterial, anti-Trypanosoma cruzi and antifungal agents. Bioorg Med Chem 2011;19:6292-301
   PubMed Web of Science ®Google Scholar
• Patel RV, Patel PK, Kumari P, et al. Synthesis of benzimidazolyl-1,3,4-oxadiazol-2ylthio-N-phenyl (benzothiazolyl) acetamides as antibacterial, antifungal and antituberculosis agents. Eur J Med Chem 2012;53:41-51
   PubMed Web of Science ®Google Scholar
• Ahsan MJ, Samy JG, Jain CB, et al. Discovery of novel antitubercular 1,5-dimethyl-2-phenyl-4-([5-(arylamino)-1,3,4-oxadiazol-2-yl]methylamino)-1,2-dihydro-3H-pyrazol-3-one analogues. Bioorg Med Chem Lett 2012;22:969-72
   PubMedGoogle Scholar
• Dürüst Y, Karakus H, Kaiser M, et al. Synthesis and anti-protozoal activity of novel dihydropyrrolo[3,4-d][1,2,3]triazoles. Eur J Med Chem 2012;48:296-304
   PubMed Web of Science ®Google Scholar
• Kumar RR, Perumal S, Menéndez JC, et al. Antimycobacterial activity of novel 1,2,4-oxadiazole-pyranopyridine/chromene hybrids generated by chemoselective 1,3-dipolar cycloadditions of nitrile oxides. Bioorg Med Chem 2011;19:3444-50
   PubMed Web of Science ®Google Scholar